论文部分内容阅读
Introduction: Elevated c-FLIP levels which are observed in many cancers,were also shown to correlate with a more aggressive tumor.
Inhibition of c-FLIP by RNAi augments TRAIL-induced apoptosis in human osteosarcoma cells
【摘 要】
：
Introduction: Elevated c-FLIP levels which are observed in many cancers,were also shown to correlate with a more aggressive tumor.
【机 构】
：
Department of Pharmacology,The First People's Hospital of Yunnan Province/The Affiliated Hospital o
【出 处】
：
第四届广州国际肿瘤学会议
【发表日期】
：
2015年期
其他文献
The conventional strategy for cancer therapy offers limited control of specificity and efficacy,study on the molecular mechanism involved in tumor growth an
会议
The epithelial-mesenchymal transition(EMT)has been shown to induce cancer stem traits.However,pharma-therapeutic approach to simultaneously prevent EMT and
会议
Randomized effects of five platinum-based chemotherapy regimens in the first treatment of advanced N
OBJECTIVE: To observe efficacy and security of five chemotherapeutic schemes including platinum on advanced nonsmall-cell lung cancer.
会议
Efficacy and security of treatment by bevacizumab and platinum-based on chemotherapy on advanced non
Objective: To evaluate efficacy and security of treatment by bevacizumab and platinum on advanced nonsmall-cell lung cancer.
The mechanism of bevacizumab combined with cisplatin interfer the invasion and metastasis of lung ad
Objective: Research on the mechanism of bevacizumab combined with cisplatin inhibits the invasion and metastasis of Lewis lung adenocarcinoma.
Esophageal squamous cell carcinoma is worse malignancy with high incidence and mortality for Chinese.
会议
Background: Leucine-rich-alpha-2-glycoprotein1(LRG1)is a novel oncogene-associated protein which has been clarified vital to the progression of human cancer
会议
Aberrant AKT activation is prevalent across multiple human cancer lineages,providing an important target for therapy.Phosphorylation plays critical roles in
会议
Validation of progression-free survival as a surrogate endpoint for overall survival in malignant me
To investigate whether progression-free survival(PFS)can be considered a surrogate endpoint for overall survival(OS)in malignant mesothelioma both at the pa
会议